

Product datasheet for **TL320355V**

FGFR3 Human shRNA Lentiviral Particle (Locus ID 2261)

Product data:

Product Type:	shRNA Lentiviral Particles
Product Name:	FGFR3 Human shRNA Lentiviral Particle (Locus ID 2261)
Locus ID:	2261
Synonyms:	ACH; CD333; CEK2; HSGFR3EX; JTK4
Vector:	pGFP-C-shLenti (TR30023)
Format:	Lentiviral particles
Components:	FGFR3 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10 ⁷ TU/ml.
RefSeq:	NM_000142 , NM_001163213 , NM_022965 , NM_001354809 , NM_001354810 , NR_148971 , NM_000142.1 , NM_000142.2 , NM_000142.3 , NM_000142.4 , NM_022965.1 , NM_022965.2 , NM_022965.3 , NM_001163213.1 , BC121175 , BC128610 , BC153824 , BC166684 , NM_000142.5
UniProt ID:	P22607
Summary:	This gene encodes a member of the fibroblast growth factor receptor (FGFR) family, with its amino acid sequence being highly conserved between members and among divergent species. FGFR family members differ from one another in their ligand affinities and tissue distribution. A full-length representative protein would consist of an extracellular region, composed of three immunoglobulin-like domains, a single hydrophobic membrane-spanning segment and a cytoplasmic tyrosine kinase domain. The extracellular portion of the protein interacts with fibroblast growth factors, setting in motion a cascade of downstream signals, ultimately influencing mitogenesis and differentiation. This particular family member binds acidic and basic fibroblast growth hormone and plays a role in bone development and maintenance. Mutations in this gene lead to craniosynostosis and multiple types of skeletal dysplasia. [provided by RefSeq, Aug 2017]
shRNA Design:	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com . If you need a special design or shRNA sequence, please utilize our custom shRNA service .



[View online »](#)

**Performance
Guaranteed:**

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).